These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 23981577

  • 1. Non-alcoholic steatohepatitis and preneoplastic lesions develop in the liver of obese and hypertensive rats: suppressing effects of EGCG on the development of liver lesions.
    Kochi T, Shimizu M, Terakura D, Baba A, Ohno T, Kubota M, Shirakami Y, Tsurumi H, Tanaka T, Moriwaki H.
    Cancer Lett; 2014 Jan 01; 342(1):60-9. PubMed ID: 23981577
    [Abstract] [Full Text] [Related]

  • 2. Enhanced development of azoxymethane-induced colonic preneoplastic lesions in hypertensive rats.
    Kochi T, Shimizu M, Ohno T, Baba A, Sumi T, Kubota M, Shirakami Y, Tsurumi H, Tanaka T, Moriwaki H.
    Int J Mol Sci; 2013 Jul 15; 14(7):14700-11. PubMed ID: 23860206
    [Abstract] [Full Text] [Related]

  • 3. (-)-Epigallocatechin-3-gallate suppresses hepatic preneoplastic lesions developed in a novel rat model of non-alcoholic steatohepatitis.
    Sumi T, Shirakami Y, Shimizu M, Kochi T, Ohno T, Kubota M, Shiraki M, Tsurumi H, Tanaka T, Moriwaki H.
    Springerplus; 2013 Jul 15; 2():690. PubMed ID: 25674420
    [Abstract] [Full Text] [Related]

  • 4. Preventive effects of (-)-epigallocatechin gallate on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BL/KsJ-db/db Mice.
    Shimizu M, Sakai H, Shirakami Y, Yasuda Y, Kubota M, Terakura D, Baba A, Ohno T, Hara Y, Tanaka T, Moriwaki H.
    Cancer Prev Res (Phila); 2011 Mar 15; 4(3):396-403. PubMed ID: 21372039
    [Abstract] [Full Text] [Related]

  • 5. (-)-Epigallocatechin gallate suppresses azoxymethane-induced colonic premalignant lesions in male C57BL/KsJ-db/db mice.
    Shimizu M, Shirakami Y, Sakai H, Adachi S, Hata K, Hirose Y, Tsurumi H, Tanaka T, Moriwaki H.
    Cancer Prev Res (Phila); 2008 Sep 15; 1(4):298-304. PubMed ID: 19138973
    [Abstract] [Full Text] [Related]

  • 6. (-)-Epigallocatechin gallate prevents carbon tetrachloride-induced rat hepatic fibrosis by inhibiting the expression of the PDGFRbeta and IGF-1R.
    Yasuda Y, Shimizu M, Sakai H, Iwasa J, Kubota M, Adachi S, Osawa Y, Tsurumi H, Hara Y, Moriwaki H.
    Chem Biol Interact; 2009 Dec 10; 182(2-3):159-64. PubMed ID: 19646978
    [Abstract] [Full Text] [Related]

  • 7. High susceptibility of obese hypertensive SHRSP.Z-Lepr(fa) /IzmDmcr rats to lipid deposition in the mesenteric artery.
    Kunimasa K, Yoshitomi H, Miura C, Mori H, Tsuchikura S, Ikeda K, Gao M, Yamori Y, Mori M.
    Clin Exp Pharmacol Physiol; 2010 Nov 10; 37(11):1102-4. PubMed ID: 20726991
    [Abstract] [Full Text] [Related]

  • 8. Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats.
    Chung S, Park CW, Shin SJ, Lim JH, Chung HW, Youn DY, Kim HW, Kim BS, Lee JH, Kim GH, Chang YS.
    Nephrol Dial Transplant; 2010 Feb 10; 25(2):389-99. PubMed ID: 19749146
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.
    Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, Bhanot S, Monia BP, Li YX, Diehl AM.
    Hepatology; 2007 Jun 10; 45(6):1366-74. PubMed ID: 17476695
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappa B pathways.
    Xiao J, Ho CT, Liong EC, Nanji AA, Leung TM, Lau TY, Fung ML, Tipoe GL.
    Eur J Nutr; 2014 Feb 10; 53(1):187-99. PubMed ID: 23515587
    [Abstract] [Full Text] [Related]

  • 18. Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis.
    Uno M, Kurita S, Misu H, Ando H, Ota T, Matsuzawa-Nagata N, Kita Y, Nabemoto S, Akahori H, Zen Y, Nakanuma Y, Kaneko S, Takamura T.
    Hepatology; 2008 Jul 10; 48(1):109-18. PubMed ID: 18571789
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.